Comparison of Ultrathin Sirolimus Eluting Biodegradable Polymer Stent with Contemporary Drug Eluting Coronary Stents – A Bayesian Network Meta-Analysis.

Sethi, Ankur

Comparison of Ultrathin Sirolimus Eluting Biodegradable Polymer Stent with Contemporary Drug Eluting Coronary Stents – A Bayesian Network Meta-Analysis.

Wednesday, May 22, 2019

Belmont Ballroom 2-3 (The Cosmopolitan of Las Vegas)

Ankur Sethi, M.B.B.S. , Mt Sinai Hospital - Cardiology, North Chicago, IL

Vamsi K. Kodumuri, M.D. , John Stroger Hospital of Cook County, Chicago, IL

Vinoy Prasad, M.D. , Loma Linda University Medical Center, Upland, CA

Ashok Chaudhary, M.D. , Rutgers RWJ Med Sch, Princeton, NJ

John Kassotis , Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Background
Newer stents with thinner struts and biodegradable polymer are thought to improve outcomes. Whether the ultrathin sirolimus (Orsiro) drug eluting stent(DES) is superior to contemporary DES is unknown. The purpose of this study was to compare outcomes of these two types of stent configurations.

Methods
A systematic search for randomized controlled trials (RCT) comparing contemporary DES was performed. A Bayesian network meta-analysis was performed using Poisson distribution.

Results
Fourteen RCT comparing six contemporary DES were included. No difference in target lesion failure or stent thrombosis were noted. Orsiro had the highest probability of superiority with the lowest target lesion failure rate.

Conclusions
Based on current evidence, Orsiro is non-inferior to all contemporary DES and our data suggests that this stent may outperform several conventional stents if studied in adequately powered large clinical trial.